Loading…
Parvovirus B19: implications for transfusion medicine. Summary of a workshop
This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients othe...
Saved in:
| Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2001-01, Vol.41 (1), p.130-135 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3 |
| container_end_page | 135 |
| container_issue | 1 |
| container_start_page | 130 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 41 |
| creator | Brown, Kevin E. Young, Neal S. Alving, Barbara M. Barbosa, Luiz H. |
| description | This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients other than those in specific risk groups. The testing of blood components for any infectious agent is usually clinically driven, and, if B19 NAT were recommended at the present time in other than plasma products, a CMV-like model might prove appropriate; that is, virus screening would be performed on blood components destined for high-risk groups only. Currently, there is insufficient evidence to recommend universal testing, especially for single units. Workshop participants recommended that basic research continue in the scientific areas addressed. If clinical trials were to be developed, participants recommended that they include special risk groups such as seronegative pregnant women and children with malignancies who are receiving chemotherapy. |
| doi_str_mv | 10.1046/j.1537-2995.2001.41010130.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70640131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70640131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3</originalsourceid><addsrcrecordid>eNqVkNFu0zAUhi3ExMrgFZAlJO6SnRPHiQ1XsLKCVG3TVgR3luPawl1SF7vZurdfonbjevKFZfs_n8_5CPmIkCOU1ekqR87qrJCS5wUA5iXCsBjku1dk8vz2mkwASswQWXFM3qa0AoBCAr4hx4hYYcHFhMyvdLwLdz72iX5D-Zn6btN6o7c-rBN1IdJt1Ovk-jRc0M4uvfFrm9Obvut0fKDBUU3vQ7xNf8PmHTlyuk32_WE_Ib_Ovy_OfmTzy9nPs6_zzDBZQyZRL4WumqVohJNWNiUYZ1hhGiZ4YUsLjRAVM9WSMQOaOxC8sZILIxxHNOyEfNpzNzH8623aqs4nY9tWr23ok6qhKgchOAS_7IMmhpSidWoT_di3QlCjTLVSozA1ClOjTPUkU-2G6g-Hb_pmmPx_7cHeEJjuA_e-tQ8vYavF9fnTacBke4xPW7t7xuh4q6qa1Vz9vpip6Z-r6fWsWqgb9giispPl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70640131</pqid></control><display><type>article</type><title>Parvovirus B19: implications for transfusion medicine. Summary of a workshop</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Brown, Kevin E. ; Young, Neal S. ; Alving, Barbara M. ; Barbosa, Luiz H.</creator><creatorcontrib>Brown, Kevin E. ; Young, Neal S. ; Alving, Barbara M. ; Barbosa, Luiz H.</creatorcontrib><description>This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients other than those in specific risk groups. The testing of blood components for any infectious agent is usually clinically driven, and, if B19 NAT were recommended at the present time in other than plasma products, a CMV-like model might prove appropriate; that is, virus screening would be performed on blood components destined for high-risk groups only. Currently, there is insufficient evidence to recommend universal testing, especially for single units. Workshop participants recommended that basic research continue in the scientific areas addressed. If clinical trials were to be developed, participants recommended that they include special risk groups such as seronegative pregnant women and children with malignancies who are receiving chemotherapy.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1046/j.1537-2995.2001.41010130.x</identifier><identifier>PMID: 11161258</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Inc</publisher><subject>and Blood Institute ; Animals ; B19 = human B19 parvovirus ; Blood - virology ; Blood Transfusion ; Humans ; Lung ; NHLBI = National Heart ; NHLBI = National Heart, Lung, and Blood Institute ; Parvoviridae Infections - diagnosis ; Parvoviridae Infections - physiopathology ; Parvoviridae Infections - prevention & control ; Parvovirus - immunology ; Parvovirus - isolation & purification ; SCD = sickle cell disease ; SD = solvent/detergent-treated ; SPV = simian parvovirus ; United States ; United States Food and Drug Administration ; Viral Vaccines</subject><ispartof>Transfusion (Philadelphia, Pa.), 2001-01, Vol.41 (1), p.130-135</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3</citedby><cites>FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23908,23909,25117,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11161258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, Kevin E.</creatorcontrib><creatorcontrib>Young, Neal S.</creatorcontrib><creatorcontrib>Alving, Barbara M.</creatorcontrib><creatorcontrib>Barbosa, Luiz H.</creatorcontrib><title>Parvovirus B19: implications for transfusion medicine. Summary of a workshop</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients other than those in specific risk groups. The testing of blood components for any infectious agent is usually clinically driven, and, if B19 NAT were recommended at the present time in other than plasma products, a CMV-like model might prove appropriate; that is, virus screening would be performed on blood components destined for high-risk groups only. Currently, there is insufficient evidence to recommend universal testing, especially for single units. Workshop participants recommended that basic research continue in the scientific areas addressed. If clinical trials were to be developed, participants recommended that they include special risk groups such as seronegative pregnant women and children with malignancies who are receiving chemotherapy.</description><subject>and Blood Institute</subject><subject>Animals</subject><subject>B19 = human B19 parvovirus</subject><subject>Blood - virology</subject><subject>Blood Transfusion</subject><subject>Humans</subject><subject>Lung</subject><subject>NHLBI = National Heart</subject><subject>NHLBI = National Heart, Lung, and Blood Institute</subject><subject>Parvoviridae Infections - diagnosis</subject><subject>Parvoviridae Infections - physiopathology</subject><subject>Parvoviridae Infections - prevention & control</subject><subject>Parvovirus - immunology</subject><subject>Parvovirus - isolation & purification</subject><subject>SCD = sickle cell disease</subject><subject>SD = solvent/detergent-treated</subject><subject>SPV = simian parvovirus</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><subject>Viral Vaccines</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqVkNFu0zAUhi3ExMrgFZAlJO6SnRPHiQ1XsLKCVG3TVgR3luPawl1SF7vZurdfonbjevKFZfs_n8_5CPmIkCOU1ekqR87qrJCS5wUA5iXCsBjku1dk8vz2mkwASswQWXFM3qa0AoBCAr4hx4hYYcHFhMyvdLwLdz72iX5D-Zn6btN6o7c-rBN1IdJt1Ovk-jRc0M4uvfFrm9Obvut0fKDBUU3vQ7xNf8PmHTlyuk32_WE_Ib_Ovy_OfmTzy9nPs6_zzDBZQyZRL4WumqVohJNWNiUYZ1hhGiZ4YUsLjRAVM9WSMQOaOxC8sZILIxxHNOyEfNpzNzH8623aqs4nY9tWr23ok6qhKgchOAS_7IMmhpSidWoT_di3QlCjTLVSozA1ClOjTPUkU-2G6g-Hb_pmmPx_7cHeEJjuA_e-tQ8vYavF9fnTacBke4xPW7t7xuh4q6qa1Vz9vpip6Z-r6fWsWqgb9giispPl</recordid><startdate>200101</startdate><enddate>200101</enddate><creator>Brown, Kevin E.</creator><creator>Young, Neal S.</creator><creator>Alving, Barbara M.</creator><creator>Barbosa, Luiz H.</creator><general>Blackwell Science Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200101</creationdate><title>Parvovirus B19: implications for transfusion medicine. Summary of a workshop</title><author>Brown, Kevin E. ; Young, Neal S. ; Alving, Barbara M. ; Barbosa, Luiz H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>and Blood Institute</topic><topic>Animals</topic><topic>B19 = human B19 parvovirus</topic><topic>Blood - virology</topic><topic>Blood Transfusion</topic><topic>Humans</topic><topic>Lung</topic><topic>NHLBI = National Heart</topic><topic>NHLBI = National Heart, Lung, and Blood Institute</topic><topic>Parvoviridae Infections - diagnosis</topic><topic>Parvoviridae Infections - physiopathology</topic><topic>Parvoviridae Infections - prevention & control</topic><topic>Parvovirus - immunology</topic><topic>Parvovirus - isolation & purification</topic><topic>SCD = sickle cell disease</topic><topic>SD = solvent/detergent-treated</topic><topic>SPV = simian parvovirus</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><topic>Viral Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, Kevin E.</creatorcontrib><creatorcontrib>Young, Neal S.</creatorcontrib><creatorcontrib>Alving, Barbara M.</creatorcontrib><creatorcontrib>Barbosa, Luiz H.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, Kevin E.</au><au>Young, Neal S.</au><au>Alving, Barbara M.</au><au>Barbosa, Luiz H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Parvovirus B19: implications for transfusion medicine. Summary of a workshop</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2001-01</date><risdate>2001</risdate><volume>41</volume><issue>1</issue><spage>130</spage><epage>135</epage><pages>130-135</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><abstract>This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients other than those in specific risk groups. The testing of blood components for any infectious agent is usually clinically driven, and, if B19 NAT were recommended at the present time in other than plasma products, a CMV-like model might prove appropriate; that is, virus screening would be performed on blood components destined for high-risk groups only. Currently, there is insufficient evidence to recommend universal testing, especially for single units. Workshop participants recommended that basic research continue in the scientific areas addressed. If clinical trials were to be developed, participants recommended that they include special risk groups such as seronegative pregnant women and children with malignancies who are receiving chemotherapy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Inc</pub><pmid>11161258</pmid><doi>10.1046/j.1537-2995.2001.41010130.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2001-01, Vol.41 (1), p.130-135 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70640131 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | and Blood Institute Animals B19 = human B19 parvovirus Blood - virology Blood Transfusion Humans Lung NHLBI = National Heart NHLBI = National Heart, Lung, and Blood Institute Parvoviridae Infections - diagnosis Parvoviridae Infections - physiopathology Parvoviridae Infections - prevention & control Parvovirus - immunology Parvovirus - isolation & purification SCD = sickle cell disease SD = solvent/detergent-treated SPV = simian parvovirus United States United States Food and Drug Administration Viral Vaccines |
| title | Parvovirus B19: implications for transfusion medicine. Summary of a workshop |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T20%3A40%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Parvovirus%20B19:%20implications%20for%20transfusion%20medicine.%20Summary%20of%20a%20workshop&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Brown,%20Kevin%20E.&rft.date=2001-01&rft.volume=41&rft.issue=1&rft.spage=130&rft.epage=135&rft.pages=130-135&rft.issn=0041-1132&rft.eissn=1537-2995&rft_id=info:doi/10.1046/j.1537-2995.2001.41010130.x&rft_dat=%3Cproquest_cross%3E70640131%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3970-91ad8a6bd8b8f9e9b40cfc32cb3852e4e0b8863c6d33c0a5f085be958c8f511c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70640131&rft_id=info:pmid/11161258&rfr_iscdi=true |